The Conversation (0)
- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Top Stocks
Top Resource Stocks
Top Tech Stocks
Top Life Science Stocks
Trending
Trending Articles
Trending Press Releases
Trending Companies
Trending Reports
Resource
Popular Lists
Investing Ideas
Outlook Reports
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
Investing Guides
Tech
Popular Lists
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
Investing Ideas
Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
Investing Guides
Life Science
Popular Lists
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Investing Guides
BioDelivery Sciences Announces BELBUCA® Patent Litigation Settlement Agreement with Teva
Feb. 06, 2018 08:40AM PST
Biotech InvestingBioDelivery Sciences (NASDAQ:BDSI) announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. that resolves BDSI’s previously reported BELBUCA® (buprenorphine) buccal film (CIII), patent litigation against Teva pending in the United States District Court for the District of Delaware. As quoted in the press release: “We …
BioDelivery Sciences (NASDAQ:BDSI) announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. that resolves BDSI’s previously reported BELBUCA® (buprenorphine) buccal film (CIII), patent litigation against Teva pending in the United States District Court for the District of Delaware.
As quoted in the press release:
“We are pleased to have resolved our BELBUCA lawsuit with Teva. We believe that this settlement, together with our previously announced settlement of the lawsuit with Teva regarding BUNAVAIL®, provide additional certainty around our patent portfolio and the future potential for our two commercialized products,” said Scott Plesha, President of BioDelivery Sciences. “Importantly, settling these lawsuits allows us to avoid future litigation costs and thus preserve capital resources.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.